

# CAMC Research Day

## Abstract Sample Packet

- Guidelines for writing an abstract
- Original Research sample abstract
- Case Report sample abstract
- CARE Checklist of information to include when writing a case report (this is for a full case report but much applies to abstracts as well)
- CAMC Research Committee abstract screening rubric

## Guidelines for Writing an Abstract

### Title:

- Short and concise
- Tells the reader what the study is about

### Authors:

- Give credit to everyone who made a substantial contribution to the work.

### Purpose:

- Presents the reason for doing the research
- States hypothesis or objective
- Limit purpose statement to about 3 sentences

### Methods:

- 2-3 sentences about the approach
- May want to state population, data variables or analytics used

### Results:

- Results should relate to the hypothesis/objective of the study.
- Significant results should include the p-value.

### Conclusion:

- Show the impact of the research
- Tell the audience why this research is of value to society, the organization

## ORIGINAL RESEARCH Example

### Example of an Abstract: (Word limit = 300)

**Title:** Treatment of acute myocardial infarction at United States academic hospitals.

**Authors:** Bradley G. Phillips, Pharm.D., Josephine M. Yim, Pharm.D., Edward J. Brown, Jr., M.D., Neville Bittar, M.D., Timothy J. Hoon, Pharm.D., Catherine Celestin, Pharm.D., Peter H. Vlasses, Pharm.D., FCCP, Jerry L. Bauman, Pharm.D., FCCP; University of Illinois at Chicago; University Hospital Consortium, Oak Brook, IL; Bronx-Lebanon Medical Center, Bronx, NY; University of Wisconsin; Bristol-Myers Squibb Company, Princeton, NJ.

**Purpose:** This study documented drug therapy received by patients surviving acute myocardial infarction (AMI) at U.S. academic hospitals in order to 1) compare prescribed drug therapy to established guidelines defined in the medical literature, and 2) evaluate evolving prescribing trends in pharmacologic management.


**Methods:** Medical records of 500 survivors of AMI admitted between April 1 and October 31, 1993 to 12 academic centers in the United States were reviewed. Patients' medical history, in-hospital course, and specific drug management prior to admission, during the first 72 hours post AMI, and at hospital discharge, were documented.

**Results:** Thrombolytic therapy was prescribed in 29% of 500 patients studied and included: intravenous streptokinase (49%), tissue-type plasminogen activator (43%), acylated plasminogen-streptokinase activator complex (5%), and intracoronary urokinase (3%). A greater proportion of eligible patients received  $\beta$ -blocker therapy than calcium channel antagonist therapy within the initial 72 hours (61% vs 40%,  $p < 0.005$ ) and at discharge (51% vs 35%,  $p < 0.005$ ). Women were less likely to receive thrombolytic therapy (OR=0.61; CI 0.54, 0.69) or  $\beta$ -blocker therapy within the first 72 hours (OR=0.61; CI 0.55, 0.67) and at hospital discharge (OR=0.53; CI 0.48, 0.58).

**Conclusions:** Streptokinase was the predominant thrombolytic agent used at academic hospitals studied during the period of data collection. Use of acute and chronic  $\beta$ -blocker therapy has now surpassed that of calcium channel antagonist therapy in this setting. These changes may be due to the impact of large clinical trials. With few exceptions, the majority of surviving patients received appropriate pharmacologic therapies during the initial 72 hours and at hospital discharge.

Abstract: Taken from the American College of Clinical Pharmacy on How to Write an Abstract.

# Case Example



Example of Abstract Format.  
From The American College of Physicians 2/26/2016

## CARE Checklist of information to include when writing a case report



Topic	Item	Checklist item description	Reported on Line	
Key Words Abstract (no references)	1	The diagnosis or intervention of primary focus followed by the words "case report" . . . . .	_____	
	2	2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" . . . . .	_____	
	3a	Introduction: What is unique about this case and what does it add to the scientific literature? . . . . .	_____	
	3b	Main symptoms and/or important clinical findings . . . . .	_____	
	3c	The main diagnoses, therapeutic interventions, and outcomes . . . . .	_____	
	3d	Conclusion—What is the main "take-away" lesson(s) from this case? . . . . .	_____	
	Introduction	4	One or two paragraphs summarizing why this case is unique ( <b>may include references</b> ) . . . . .	_____
		5a	De-identified patient specific information . . . . .	_____
		5b	Primary concerns and symptoms of the patient . . . . .	_____
		5c	Medical, family, and psycho-social history including relevant genetic information . . . . .	_____
5d		Relevant past interventions with outcomes . . . . .	_____	
Clinical Findings	6	Describe significant physical examination (PE) and important clinical findings . . . . .	_____	
	7	Historical and current information from this episode of care organized as a timeline . . . . .	_____	
Diagnostic Assessment	8a	Diagnostic testing (such as PE, laboratory testing, imaging, surveys) . . . . .	_____	
	8b	Diagnostic challenges (such as access to testing, financial, or cultural) . . . . .	_____	
	8c	Diagnosis (including other diagnoses considered) . . . . .	_____	
	8d	Prognosis (such as staging in oncology) where applicable . . . . .	_____	
Therapeutic Intervention	9a	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) . . . . .	_____	
	9b	Administration of therapeutic intervention (such as dosage, strength, duration) . . . . .	_____	
	9c	Changes in therapeutic intervention (with rationale) . . . . .	_____	
Follow-up and Outcomes	10a	Clinician and patient-assessed outcomes (if available) . . . . .	_____	
	10b	Important follow-up diagnostic and other test results . . . . .	_____	
	10c	Intervention adherence and tolerability (How was this assessed?) . . . . .	_____	
	10d	Adverse and unanticipated events . . . . .	_____	
Discussion	11a	A scientific discussion of the strengths AND limitations associated with this case report . . . . .	_____	
	11b	Discussion of the relevant medical literature <b>with references</b> . . . . .	_____	
	11c	The scientific rationale for any conclusions (including assessment of possible causes) . . . . .	_____	
Patient Perspective	11d	The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion . . . . .	_____	
	12	The patient should share their perspective in one to two paragraphs on the treatment(s) they received . . . . .	_____	
Informed Consent	13	Did the patient give informed consent? Please provide if requested . . . . .	_____	

Yes  No

Research Day Abstract  
Submission Screening Guide

Original

Pre-screening for word limit and IRB approval done by research staff. Covered quickly during meeting.

	A	B	C
Follows format Intro/Background	Concise, purpose, hypothesis, question(s) clearly stated with briefly stated supporting background	Components not quite as concise but stated well enough that the reader can quickly understand and move on.	Less concise, reader might have to read more than once to understand components, background missing or too lengthy.
Methods	Method stated and appropriate for study, sample size, time frame, how data obtained, description of statistical analysis present.	Components present but may be less clear.	Missing key component or detail that makes it difficult for the reader to determine if it's appropriate.
Results	Final (pilot might be a "-“ for example), clearly stated statistical significance.	Preliminary but complete enough to report meaningful results. Contains statistical significance. (might be a "-“ if specific statistical significance details omitted.	Early results, missing statistical details.
Conclusions	Conclusions relates back to purpose and not overstated. Describes how work contributes to field, how it might apply to clinical care, and/or how it might support additional study.	Conclusion relates back to purpose but less concise. Not as clear as how it contributes to field, applies to clinical care and/or supports additional study.	If any of the above are "C" need go no further.
Grammar/typo's, spelling	None	None/minimal	

Overall Grade A, B, C. A+ would be considered outstanding, A "-“ would be something that scored no more than 1 "B" in any category. B would be more than one "B" scores in any category. The difference between an A- and B+ would typically be the relevance of the study. For example a submission that scored mostly "B" but has high clinical relevance that would be important to disseminate would earn a "+“

Research Day Abstract  
Submission Screening Guide

Given the number of Oral slots being small, typically scores below “B+” or “occasionally “B” do not make it to the oral category.

Overall C scores (even plus or minus) are not selected for oral or poster. A C+ could conceivably be upgraded to B- if the due to subject relevance.

We always consider this a learning experience as well and opportunity to disseminate locally. It’s recommended for those scoring less than an A but selected for oral or poster to work with their mentor in making improvements.

Case reports

A	B	C
Rare, not overstated as rare when it’s not, but rare enough and with clinical relevance that makes it a standout.	Not quite as rare but still rare enough that clinical relevance is notable.	Not that rare. Somewhat rare but patient received standard of care with no new or unique observations.
Well organized, readable, provides statement of relevance of adding to literature or clinical care. Contains follow-up (what happened to the patient) if possible.	Slightly less organized but very readable, has relevance but not so clearly stated but could be improved upon if selected.	Hard to follow. Too short to cover important elements of case. Low level of relevance.

A’s typically selected for Oral. Clinical relevance/need for dissemination should be considered in borderline situations (using + or -).

Oftentimes, the committee brief discussion results in + or – designation. Grading by committee members often very close and selection moves quickly. If a committee member scores somewhat differently, he/she can explain why and that can influence others. Expertise of committee members are very helpful, especially when determining importance of dissemination to a clinical audience.